Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging

• Status: Unknown status
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluate the efficacy of 68Ga-NOTA-3PTATE-RGD in lung cancer patients and neuroendocrine neoplam patients. A single dose of 111-185 Mega-Becquerel (MBq) 68Ga-NOTA-3P-TATE-RGD will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Peking Union Medical College Hospital

Criteria

Inclusion Criteria:

• Neoplasm identified by X-ray, ultrasound or MRI as lung cancer or neuroendocrine tumors

• To provide basic information and sign the written informed consent.

Exclusion Criteria:

• Consisted of conditions of mental illness;

• Severe liver or kidney disease with serum creatinine > 3.0 mg/dl (270 μΜ) or any hepatic enzyme level 5 times or more than normal upper limit;

• Severe allergy or hypersensitivity to IV radiographic contrast

• Claustrophobia to accept the PET/CT scanning

• Pregnancy or breast feeding